Intellia’s CRISPER/Cas9 and Teneobio’s UniAb technology providing a new dimension to cell therapy
A clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb), Teneobio and a leading genome editing company focused on developing proprietary curative therapeutics using the CRISPR/Cas9 system i.e Intellia therapeutics […]